IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Examiner: Krishnan, Ganapathy

Application No.: 10/699,967

Filed: 11/03/2003

GLOMBIK, et al.

Title: Combination Product Of A 1,4-

Benzothiepine 1,1-Dioxide **Compound With At Least One** Other Active Ingredient And The

Use Of The Product

Art Unit: 1623 I hereby certify that this correspondence is being deposited with the United

States Postal Service with sufficient postage for first class mail in an

envelope addressed to the address below, or being facsimile transmitted to the USPTO, on the date indicated below. Date of Deposit April 21, 2005

Printed Name of Person Signing Certificate Paul Irvine

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

04/26/2005 L\UNDIM1 00000060 181982 10699967

01 FC:1806

180.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#IFW

In re Application of GLOMBIK, et al.

Application No.: 10/699,967

Filed:

11/03/2003

Title: Combination Product Of A 1,4-Benzothiepine 1,1-Dioxide Compound With At Least One Other Active Ingredient And The Use Of The Product

APR 2 5 2005

Examiner: Krishnan, Ganapathy

Art Unit:

1623

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the address below, or being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit April 21, 2005

Printed Name of Person Signing Certificate Paul Irvine

Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00.

The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

James W. Bolcsak, Reg. No. 39,912

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**5922**Telefax (908) 231-2626

This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

James W. Bolcsak, Reg. No. 39,912

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-5922 Telefax (908) 231-2626

Aventis Docket No. DEAV2001/0041 US CNT

| Please type a plus sign (+) inside this box → | V |
|---|---|
|---|---|

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3


| Complete if Known | | | | | | | |
|------------------------|--------------------------|--|--|--|--|--|--|
| Application Number | 10/699,967 | | | | | | |
| Filing Date | 11-03-2003 | | | | | | |
| First Named Inventor | GLOMBIK, et al. | | | | | | |
| Group Art Unit | | | | | | | |
| Examiner Name | | | | | | | |
| Attorney Docket Number | DEAV2001/0041 - US - CNT | | | | | | |

| U.S. PATENT DOCUMENTS | | | | | | | | |
|-----------------------|----------------|--|---|--|---|--|--|--|
| Cite No.1 | Number Kind (| Code ² | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | US2003/0191174 | | IKUTA, et al. | 10-09-2003 | | | | |
| | 5,190,923 | | VINCENT, et al. | 03-02-1993 | | | | |
| | 6221633 | | ERTL, et al. | 04-24-2001 | | | | |
| | 6221897 | | BARINGHAUS | 04-24-2001 | | | | |
| | 6245744 | | BARINGHAUS | 06-12-2001 | | | | |
| | 6342512 | | KIRSCH | 01-29-2002 | | | | |
| | 6380230 | | BRODIN, et al. | 04-30-2002 | | | | |
| | 6387944 | | BARINGHAUS | 05-14-2002 | | | | |
| | 6498156 | | GLOMBIK | 12-24-2002 | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | Cite No.¹ Number US2003/0191174 5,190,923 6221633 6221897 6245744 6342512 6380230 6387944 | No.1 Number (if known) US2003/0191174 5,190,923 6221633 6221897 6245744 6342512 6380230 6387944 | U.S. Patent Document Name of Patentee or Applicant of Cited Document | U.S. Patent Document Name of Patentee or Applicant of Cited Document Number Name of Patentee or Applicant of Cited Document Number Name of Patentee or Applicant of Cited Document Number Name of Patentee or Applicant of Cited Document Number Name of Patentee or Applicant of Cited Document Number Number | | | |

| | | | | FC | REIGN PATENT DOCUMEN | TS | | |
|-----------------------|--|----|-------------------|---------------------------------|----------------------------|--|--|-----|
| Examiner Initials* | | | Foreign Patent Do | Cument Kind Cod (if know) | Annicant of Cited Cocument | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | 1.e |
| | | wo | 00/38725 | | KELLER, et al. | 07-06-2000 | | |
| | | wo | 00/40569 | | HODSON, et al. | 07-13-2000 | | |
| | | wo | 00/63208 | | DORWALD, et al. | 10-26-2000 | | |
| | | WO | 00/66585 | | HORVATH | 11-09-2000 | | |
| | | wo | 00/71549 | | BROUGH, et al. | 11-30-2000 | | |
| | | wo | 00/78312 | | SAHOO, et al. | 12-28-2000 | | |
| | | wo | 01/09111 | | BRINER, et al. | 02-08-2001 | | |
| | | WO | 01/85695 | | LI, et al. | 11-15-2001 | | |
| | | wo | 01/91752 | | BAKSHI, et al | 12-06-2001 | | |
| | | wo | 97/26265 | | NIELSEN, et al. | 07-24-1997 | | |

| Examiner | Date | |
|-----------|----------------|--|
| Signature | Considered | |

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| lease ty | /pe a | plus | sign | (+) | inside | this | box | -> | v |
|----------|-------|------|------|-----|--------|------|-----|----|---|
|----------|-------|------|------|-----|--------|------|-----|----|---|

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


| Substi | tute for form 1449A/PTC |) | - | Complete if Known | | | |
|--------|-------------------------|--------|--------------|------------------------|--------------------------|--|--|
| | | | 201 00112 | Application Number | 10/699,967 | | |
| INF | ORMATION | DI | SCLOSURE | Filing Date | 11-03-2003 | | |
| ST | ATEMENT B | YA | APPLICANT | First Named Inventor | GLOMBIK, et al. | | |
| | | | | Group Art Unit | | | |
| | (use as many she | ets as | s necessary) | Examiner Name | | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | DEAV2001/0041 - US - CNT | | |

| | U.S. PATENT DOCUMENTS | | | | | | | | |
|-----------------------|--------------------------|----------------------|---|---|--|--|--|--|--|
| Examiner Initials* | Cite No. ¹ | U.S. Paten Number | t Document Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | 1881 | | | | * | | | |
| | | | | | | | | | |
| | | | | - " | | | | | |
| | | | \longrightarrow | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | \longrightarrow | | | <u></u> | | | |
| | | | \longrightarrow | | | , | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | + | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | + + | | | | |
| | | | | | - | | | | |
| | | | | | | | | | |
| | | | | - | 1 | | | | |
| | | l | | | | | | | |

| | , and the second | , and the second | | FOR | EIGN PATENT DOCUMENT | TS | | |
|-----------------------|--|--|--|--|--|--|--|---------|
| Examiner Initials* | Cite No. [†] | Office | Foreign Patent Do Number ⁴ | cument Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Т6 |
| | | wo | 97/41097 | | LOHRAY, et al. | 11-06-1997 | | |
| | | wo | 98/08871 | | KNUDSEN, et al. | 03-05-1998 | | |
| | | wo | 99/03861 | | NIELSEN, et al. | 01-28-1999 | | |
| | | | | | | | | + |
| | | | | | | | | \perp |
| | | | | | | | | ┿ |
| <u> </u> | | | , , ,,,,, | | | | | + |
| | | | | | | †*** | | \top |

| Examiner | Date |
|-----------|------------|
| Signature | Considered |

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | | 1 | - |
|-----|------|--------|--------|-----|--------|------|-----|---|----|
| ase | type | a plus | sign (| (+) | inside | this | box | → | ۱. |

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

3

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

3

| Complete if Known | | | | | | | |
|------------------------|--------------------------|--|--|--|--|--|--|
| Application Number | 10/699,967 | | | | | | |
| Filing Date | 11-03-2003 | | | | | | |
| First Named Inventor | GLOMBIK, et al. | | | | | | |
| Group Art Unit | | | | | | | |
| Examiner Name | | | | | | | |
| Attorney Docket Number | DEAV2001/0041 - US - CNT | | | | | | |

| OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS | | | | | | | |
|---|--------------|---|----|--|--|--|--|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | | | | |
| | | ASAKAWA, A., et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research, 2001, Vol. 33(9), pp 554-558 | | | | | |
| | | LEE Daniel W., et al., Leptin Agonists As A Potential Approach To The Treatment Of Obesity, Drugs Of The Future, (2001), Vol. 26, No. 9, pp. 873 - 881 | | | | | |
| | | SALVADOR Javier, et al., Perspectives in the Therapeutic Use of Leptin, Expert Opin. Pharmacother. (2001), Vol. 2(10), pp 1615-1622 | | | | | |
| | | ZUNFT, H. et al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Therapy, 2001, Vol. 18(5), pp 230-236 | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Examiner | | Date | |
|-----------|--|------------|--|
| Signature | | Considered | |

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.